THE PRESENT INVENTORS SUCCEEDED IN DISCOVERING SPECIFIC AMINO ACID MUTATIONS IN THE VARIABLE REGION, FRAMEWORK REGION, AND CONSTANT REGION OF TOCILIZUMAB, AND THIS ENABLES TO REDUCE IMMUNOGENICITY RISK AND THE HETEROGENEITY ORIGINATED FROM DISULFIDE BONDS IN THE HINGE REGION, AS WELL AS TO IMPROVE ANTIGEN BINDING ACTIVITY, PHARMACOKINETICS, STABILITY UNDER ACIDIC CONDITIONS, AND STABILITY IN HIGH CONCENTRATION PREPARATIONS.